Article Details

BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche

Retrieved on: 2022-06-03 19:24:01

Tags for this article:

Click the tags to see associated articles and topics

BMS bets $4.1B on lung cancer drug that could best products from Pfizer, Roche. View article details on HISWAI: https://medcitynews.com/2022/06/bms-bets-4-1b-on-lung-cancer-drug-that-could-best-products-from-pfizer-roche/

Excerpt

Pfizer's Xalkori and Roche drug Rozlytrek have FDA approvals for treating ROS1-positive NSCLC that has spread. Meanwhile, Rozlytrek and Bayer drug ...

Article found on: medcitynews.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up